NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 20 04:00PM ET
4.29
Dollar change
+0.29
Percentage change
7.36
%
Index- P/E- EPS (ttm)-2.54 Insider Own22.55% Shs Outstand1.60M Perf Week42.86%
Market Cap7.03M Forward P/E- EPS next Y- Insider Trans-0.81% Shs Float1.27M Perf Month62.33%
Enterprise Value6.71M PEG- EPS next Q- Inst Own4.32% Short Float3.37% Perf Quarter193.84%
Income-4.07M P/S703.00 EPS this Y- Inst Trans55.39% Short Ratio0.09 Perf Half Y161.59%
Sales0.01M P/B6.49 EPS next Y- ROA-99.82% Short Interest0.04M Perf YTD125.20%
Book/sh0.66 P/C21.97 EPS next 5Y- ROE-139.06% 52W Range1.31 - 8.30 Perf Year-55.31%
Cash/sh0.20 P/FCF- EPS past 3/5Y62.43% 51.16% ROIC-384.78% 52W High-48.32% Perf 3Y-96.51%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-70.71% - Gross Margin-2380.00% 52W Low226.56% Perf 5Y-99.16%
Dividend TTM- EV/Sales671.00 EPS Y/Y TTM84.81% Oper. Margin-41630.00% Volatility4.04% 5.51% Perf 10Y-99.70%
Dividend Ex-Date- Quick Ratio1.00 Sales Y/Y TTM66.67% Profit Margin-40710.00% RSI (14)78.25 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio1.00 EPS Q/Q36.21% SMA2042.92% Beta-1.09 Target Price1125.00
Payout- Debt/Eq0.00 Sales Q/Q100.00% SMA5053.05% Rel Volume0.07 Prev Close4.00
Employees1 LT Debt/Eq0.00 Earnings- SMA20089.11% Avg Volume482.53K Price4.29
IPOAug 22, 2005 Option/ShortNo / Yes EPS/Sales Surpr.-14.29% - Trades Volume34,080 Change7.36%
Date Action Analyst Rating Change Price Target Change
Oct-04-22Resumed Wells Fargo Overweight $3
Jun-18-25 09:52AM
May-14-25 08:00AM
Oct-11-24 08:57AM
May-15-24 10:55PM
Apr-08-24 12:52PM
07:57AM Loading…
Dec-18-23 07:57AM
Nov-14-23 07:56AM
07:30AM
Aug-14-23 04:05PM
Jun-29-23 07:00AM
May-25-23 05:00PM
May-10-23 07:00AM
May-03-23 08:30AM
Apr-26-23 12:30PM
Mar-30-23 07:00AM
05:30PM Loading…
Mar-29-23 05:30PM
Mar-07-23 07:00AM
Feb-28-23 04:01PM
Feb-17-23 05:47AM
Jan-09-23 08:30AM
Nov-29-22 09:01AM
Nov-28-22 04:01PM
Nov-14-22 07:00AM
Nov-08-22 08:30AM
Nov-07-22 08:00AM
Sep-21-22 08:30AM
Sep-07-22 08:30AM
Sep-06-22 08:00AM
Aug-24-22 03:00PM
Aug-15-22 07:00AM
08:50AM Loading…
Aug-08-22 08:50AM
Aug-04-22 05:00PM
Jul-06-22 09:31AM
Jun-30-22 07:07AM
Jun-27-22 08:00AM
Jun-01-22 08:30AM
May-26-22 05:01PM
May-16-22 07:30AM
May-12-22 11:48AM
May-10-22 08:30AM
May-09-22 08:30AM
May-02-22 04:31PM
08:30AM
Mar-30-22 07:30AM
Mar-22-22 01:58PM
Mar-16-22 08:30AM
Mar-08-22 04:05PM
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vieser JaimeDirectorDec 31 '24Sale2.013,0006,02225,894Jan 03 04:34 PM
Vieser JaimeDirectorDec 31 '24Proposed Sale2.173,0006,510Dec 31 05:10 PM